Syndecan-4 as a Biomarker to Predict Clinical Outcome for Glioblastoma Multiforme Treated with WT1 Peptide Vaccine

References

• Drummond IA, Madden SL, Rohwer-Nutter P, Bell GI, Sukhatme VP, Rauscher FJ 3rd. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 257(5070), 674–678 (1992).
   PubMed Web of Science ®Google Scholar
• Hewitt SM, Hamada S, Mcdonnell TJ, Rauscher FJ 3rd, Saunders GF. Regulation of the proto-oncogenes BCL-2 and c-MYC by the Wilms’ tumor suppressor gene WT1. Cancer Res. 55(22), 5386–5389 (1995).
   PubMed Web of Science ®Google Scholar
• Kim J, Prawitt D, Bardeesy N et al. The Wilms’ tumor suppressor gene (WT1) product regulates Dax-1 gene expression during gonadal differentiation. Mol. Cell. Biol. 19(3), 2289–2299 (1999).
   PubMed Web of Science ®Google Scholar
• Sugiyama H. Wilms’ tumor gene WT1: its oncogenic function and clinical application. Int. J. Hematol. 73(2), 177–187 (2001).
   PubMed Web of Science ®Google Scholar
• Nakatsuka S, Oji Y, Horiuchi T et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod. Pathol. 19(6), 804–814 (2006).
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res. 15(17), 5323–5337 (2009).
   PubMed Web of Science ®Google Scholar
• Coosemans A, Vanderstraeten A, Tuyaerts S et al. Wilms’ tumor gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a Phase I/II clinical trial. Anticancer Res. 33(12), 5495–5500 (2013).
   PubMed Web of Science ®Google Scholar
• Van Driessche A, Van de Velde AL, Nijs G et al. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a Phase I dose-escalation clinical trial. Cytotherapy 11(5), 653–668 (2009).
   PubMed Web of Science ®Google Scholar
• Coosemans A, Vanderstraeten A, Tuyaerts S et al. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Res. 33(9), 3855–3859 (2013).
   PubMed Web of Science ®Google Scholar
• Izumoto S, Tsuboi A, Oka Y et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J. Neurosurg. 108(5), 963–971 (2008).
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Tsuboi A, Chiba Y et al. Immunotherapy targeting the Wilms’ tumor 1 gene product for patients with malignant brain tumors. Brain Nerve 61(7), 805–814 (2009).
   PubMedGoogle Scholar
• Chiba Y, Hashimoto N, Tsuboi A et al. Effects of concomitant temozolomide and radiation therapies on WT1-specific T-cells in malignant glioma. Jpn. J. Clin. Oncol. 40(5), 395–403 (2010).
   PubMed Web of Science ®Google Scholar
• Chiba Y, Hashimoto N, Tsuboi A et al. Prognostic value of WT1 protein expression level and MIB-1 staining index as predictor of response to WT1 immunotherapy in glioblastoma patients. Brain Tumor Pathol. 27(1), 29–34 (2010).
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Tsuboi A, Kagawa N et al. Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response. Cancer Immunol. Immunother. 64(6), 707–716 (2015).
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101(38), 13885–13890 (2004).
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA 107(31), 13824–13829 (2010).
   PubMed Web of Science ®Google Scholar
• Hashii Y, Sato-Miyashita E, Matsumura R et al. WT1 peptide vaccination following allogeneic stem cell transplantation in pediatric leukemic patients with high risk for relapse: successful maintenance of durable remission. Leukemia 26(3), 530–532 (2012).
   PubMed Web of Science ®Google Scholar
• Tsuboi A, Oka Y, Kyo T et al. Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease. Leukemia 26(6), 1410–1413 (2012).
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H. WT1 peptide vaccine for the treatment of cancer. Curr. Opin. Immunol. 20(2), 211–220 (2008).
   PubMed Web of Science ®Google Scholar
• Narita M, Masuko M, Kurasaki T et al. WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int. J. Med. Sci. 7(2), 72–81 (2010).
   PubMed Web of Science ®Google Scholar
• Oji Y, Oka Y, Nishida S et al. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. Eur. J. Haematol. 85(4), 358–360 (2010).
   PubMed Web of Science ®Google Scholar
• Kawakami M, Oka Y, Tsuboi A et al. Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. Int. J. Hematol. 85(5), 426–429 (2007).
   PubMed Web of Science ®Google Scholar
• Ohno S, Kyo S, Myojo S et al. Wilms’ tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res. 29(11), 4779–4784 (2009).
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Murakami M et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78(1), 56–61 (2003).
   PubMed Web of Science ®Google Scholar
• Tsuboi A, Oka Y, Nakajima H et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int. J. Hematol. 86(5), 414–417 (2007).
   PubMed Web of Science ®Google Scholar
• Nishioka M, Tanemura A, Nishida S et al. Vaccination with WT-1 (Wilms’ tumor gene-1) peptide and BCG-CWS in melanoma. Eur. J. Dermatol. 22(2), 258–259 (2012).
   PubMed Web of Science ®Google Scholar
• Ohta H, Hashii Y, Yoneda A et al. WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report. Pediatr. Hematol. Oncol. 26(1), 74–83 (2009).
   PubMed Web of Science ®Google Scholar
• Tsuboi A, Oka Y, Osaki T et al. WT1 peptide-based immunotherapy for patients with lung cancer: report of two cases. Microbiol. Immunol. 48(3), 175–184 (2004).
   PubMed Web of Science ®Google Scholar
• Takahara A, Koido S, Ito M et al. Gemcitabine enhances Wilms’ tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunol. Immunother. 60(9), 1289–1297 (2011).
   PubMed Web of Science ®Google Scholar
• Nishida S, Koido S, Takeda Y et al. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J. Immunother. 37(2), 105–114 (2014).
   PubMed Web of Science ®Google Scholar
• Dohi S, Ohno S, Ohno Y et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Res. 31(7), 2441–2445 (2011).
   PubMed Web of Science ®Google Scholar
• Miyatake T, Ueda Y, Morimoto A et al. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a Phase II trial. J. Cancer Res. Clin. Oncol. 139(3), 457–463 (2013).
   PubMed Web of Science ®Google Scholar
• Ohno S, Dohi S, Ohno Y et al. Immunohistochemical detection of WT1 protein in endometrial cancer. Anticancer Res. 29(5), 1691–1695 (2009).
   PubMed Web of Science ®Google Scholar
• Sasabe E, Hamada F, Iiyama T, Udaka K, Sugiyama H, Yamamoto T. Wilm’s tumor gene WT1 peptide immunotherapy for pulmonary metastasis from adenoid cystic carcinoma of the salivary gland. Oral Oncol. 47(1), 77–78 (2011).
   PubMed Web of Science ®Google Scholar
• Shirakata T, Oka Y, Nishida S et al. WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer. Anticancer Res. 32(3), 1081–1085 (2012).
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Bauchet L, Davis FG et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 16(7), 896–913 (2014).
   PubMed Web of Science ®Google Scholar
• Ogi C, Aruga A. New concepts of biomarkers and clinical outcomes for therapeutic cancer vaccines in clinical trials. Immunotherapy 6(10), 1025–1036 (2014).
   PubMed Web of Science ®Google Scholar
• Shippy R, Fulmer-Smentek S, Jensen RV et al. Using RNA sample titrations to assess microarray platform performance and normalization techniques. Nat. Biotechnol. 24(9), 1123–1131 (2006).
   PubMed Web of Science ®Google Scholar
• Allison DB, Cui X, Page GP, Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat. Rev. Genet. 7(1), 55–65 (2006).
   PubMed Web of Science ®Google Scholar
• Shi L, Reid LH, Jones WD et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24(9), 1151–1161 (2006).
   PubMed Web of Science ®Google Scholar
• NCBI nucleotide database. http://www.ncbi.nlm.nih.gov/nuccore.
   Google Scholar
• The R Project for Statistical Computing. www.r-project.org.
   Google Scholar
• Chung JS, Dougherty I, Cruz PD Jr, Ariizumi K. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation. J. Immunol. 179(9), 5778–5784 (2007).
   PubMed Web of Science ®Google Scholar
• Chung JS, Sato K, Dougherty Ii, Cruz PD Jr, Ariizumi K. DC-HIL is a negative regulator of T lymphocyte activation. Blood 109(10), 4320–4327 (2007).
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10(1), 48–57 (2009).
   PubMed Web of Science ®Google Scholar
• Teixe T, Nieto-Blanco P, Vilella R, Engel P, Reina M, Espel E. Syndecan-2 and -4 expressed on activated primary human CD4+ lymphocytes can regulate T cell activation. Mol. Immunol. 45(10), 2905–2919 (2008).
   PubMed Web of Science ®Google Scholar
• Okuyama E, Suzuki A, Murata M et al. Molecular mechanisms of syndecan-4 upregulation by TNF-alpha in the endothelium-like EAhy926 cells. J. Biochem. 154(1), 41–50 (2013).
   PubMed Web of Science ®Google Scholar
• Chung JS, Tomihari M, Tamura K, Kojima T, Cruz PD Jr, Ariizumi K. The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease. Immunology 138(2), 173–182 (2013).
   PubMed Web of Science ®Google Scholar
• Chung JS, Yudate T, Tomihari M, Akiyoshi H, Cruz PD Jr, Ariizumi K. Binding of DC-HIL to dermatophytic fungi induces tyrosine phosphorylation and potentiates antigen presenting cell function. J. Immunol. 183(8), 5190–5198 (2009).
   PubMed Web of Science ®Google Scholar
• Chung JS, Tamura K, Akiyoshi H, Cruz PD Jr, Ariizumi K. The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells. J. Immunol. 192(6), 2576–2584 (2014).
   PubMed Web of Science ®Google Scholar
• Ishiguro K, Kadomatsu K, Kojima T et al. Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J. Biol. Chem. 276(50), 47483–47488 (2001).
   PubMed Web of Science ®Google Scholar
• Tanino Y, Chang MY, Wang X et al. Syndecan-4 regulates early neutrophil migration and pulmonary inflammation in response to lipopolysaccharide. Am. J. Respir. Cell Mol. Biol. 47(2), 196–202 (2012).
   PubMed Web of Science ®Google Scholar
• Smith MF Jr, Novotny J, Carl VS, Comeau LD. Helicobacter pylori and toll-like receptor agonists induce syndecan-4 expression in an NF-kappaB-dependent manner. Glycobiology 16(3), 221–229 (2006).
   PubMed Web of Science ®Google Scholar
• Boyanovsky BB, Shridas P, Simons M, Van der Westhuyzen DR, Webb NR. Syndecan-4 mediates macrophage uptake of group V secretory phospholipase A2-modified LDL. J. Lipid Res. 50(4), 641–650 (2009).
   PubMed Web of Science ®Google Scholar
• Li J, Brown LF, Laham RJ, Volk R, Simons M. Macrophage-dependent regulation of syndecan gene expression. Circ. Res. 81(5), 785–796 (1997).
   PubMed Web of Science ®Google Scholar
• Komatsu N, Matsueda S, Tashiro K et al. Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer 118(12), 3208–3221 (2012).
   PubMed Web of Science ®Google Scholar